Tablets are so pointless at my school. My district recently received Nooks for each student-no student uses them and no teacher encourages them because they aren’t effective in the classroom! As a teacher, how do you know your student isn’t playing a game on the tablet? Plus, they hurt my eyes and give me headaches; that means I would have to take more breaks during homework sessions. As a high school student, I MUCH rather be able to flip through pages quickly. STOP pushing technology onto students simply because it fits YOUR tree-hugger agenda! If you’re not in school taking these ridiculous standardized tests on computers and doing tiring and tedious math problems on a website (teachers are now, by the way, encouraged to leave the teaching to a faulty computer program) then you have no room to talk!
In January 2014, Novartis announced plans to cut 500 jobs from its pharmaceuticals division.  In February 2014, Novartis announced that it has acquired CoStim Pharmaceuticals.  In May 2014, Novartis bought the rights to market Ophthotech 's Fovista (an anti- PDGF aptamer , also being investigated for use in combination with anti- VEGF treatments) outside the United States for up to $1 billion.  Novartis will acquire exclusive rights to market the eye drug outside of America whilst retaining US marketing rights. The company agreed to pay Ophthotech $200 million upfront, and $130 million in milestone payments relating to Phase III trials.  Ophthotech is also eligible to receive up to $300 million dependent upon future marketing approval milestones outside of America and up to $400 million relating to sales milestones.  In September 2014, Ophthotech received its first $50 million phase III trial milestone payment from Novartis.  In April 2014, Novartis announced that it would acquire GlaxoSmithKline 's cancer drug business for $16 billion as well as selling its vaccines business to GlaxoSmithKline for $ billion.  In August 2014 Genetic Engineering & Biotechnology News reported that Novartis had acquired a 15% stake in Gamida Cell for $35 million, with the option to purchase the whole company for approximately $165 million.  In October 2014, Novartis announced its intention to sell its influenza vaccine business (inclusive of its development pipeline), subject to regulatory approval, to CSL for $275 million.